<DOC>
	<DOCNO>NCT01938716</DOCNO>
	<brief_summary>The goal clinical research study learn gemcitabine give surgery enter pancreas cancer cell patient already receive chemotherapy radiation . Gemcitabine drug use treat pancreatic cancer . However , previously study gemcitabine enter pancreatic cancer cell . Gemcitabine design block growth cancer cell , may cause cancer cell die .</brief_summary>
	<brief_title>Gemcitabine Pharmacokinetics After Preoperative Chemoradiation Therapy</brief_title>
	<detailed_description>Surgery : If agree take part study , surgery perform way would even take part study . You sign separate consent form surgery . The length surgery time anesthesia change take part study . During surgery , routine procedure learn disease spread area . If disease spread beyond pancreas , surgical removal possible . If sign spread reason cancer remove , surgeon begin process remove disease . Study Drug Administration : You receive gemcitabine vein surgery . Gemcitabine give infusion catheter place arm chest operating room asleep . The infusion catheter standard-of-care procedure participant surgery . You ask sign separate consent form infusion catheter . The infusion take either 50 75 minute , depend upon join study . The first 5 participant receive gemcitabine 50 minute rest participant receive gemcitabine 75 minute . Blood Tissue Collection : Up 8 blood sample ( 1 tablespoon time ) draw 70-95 minute pharmacokinetic ( PK ) test day surgery . PK test measure level study drug blood different time point . The blood also use biomarker test . Biomarkers chemical marker find blood tissue may relate reaction study drug . Some tumor tissue normal tissue remove surgery collect learn gemcitabine able enter tissue cell biomarker test . Length Participation : If reason surgery surgeon decide removal pancreas possible , receive gemcitabine participation study end . Your active participation study surgery complete follow-up . Follow-Up : One ( 1 ) time day hospital recover surgery time routine clinic visit phone call least 1 time week , 30 day surgery , ask side effect . This investigational study . Gemcitabine FDA approve commercially available treatment pancreatic cancer . Its use surgery investigational . Up 40 patient take part study . All enrol MD Anderson .</detailed_description>
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<criteria>1 . Cytologic histologic proof adenocarcinoma pancreas require . Patients Islet cell tumor eligible . 2 . Patients know metastasis . 3 . Patients must potentially resectable borderline resectable pancreatic cancer agree undergo surgical resection MD Anderson Cancer Center operable . They undergo stag ( physical examination , chest xray , contrast enhance CT MRI ( CT contraindicate ) and/or angiogram ) determine resectability . 4 . Patients complete radiation chemotherapy either fluoropyrimidines ( 5FU capecitabine ) gemcitabine radiosensitizing agent part preoperative therapy . Previous systemic chemotherapy alone allow . Preoperative therapy complete least 4 week prior surgery . 5 . Patients Karnofsky performance status &gt; 70 eligible . 6 . There upper age restriction . Patients le 18 year age exclude protocol adenocarcinoma pancreas rarely see pediatric population . 7 . Adequate renal bone marrow function : Leukocytes &gt; = 3,000/uL ; Absolute neutrophil count &gt; = 1,500/uL ; Platelets &gt; = 100,000/Ul ; Serum creatinine &lt; = 2.0 mg/dL ; Creatinine clearance &gt; = 60 ml/min ( calculate Cockcroft Gault equation ) 8 . Adequate Hepatic function ( endoscopic percutaneous drainage need ) : Total bilirubin &lt; = 3 X institutional upper limit normal ( ULN ) ; AST ( SGOT ) /ALT ( SGPT ) &lt; = 5 X institutional ULN 9 . Patients must fever evidence infection coexist medical condition would preclude administration gemcitabine . Patients uncontrolled congestive heart failure , unstable angina myocardial infarction within 3 month exclude . 10 . Patient pregnant . Women childbearing potential ( i.e. , woman premenopausal surgically sterile ) must use acceptable contraceptive method ( abstinence , intrauterine device [ IUD ] , oral contraceptive double barrier device ) refrain breastfeeding , specify informed consent . 11 . Patients must sign studyspecific consent form . 1 . Major cardiovascular pulmonary comorbidity precludes use general anesthesia ( NYHA [ New York Heart Association ] Class III IV ) . 2 . Identification metastatic disease . 3 . Patients know hypersensitivity Gemcitabine . 4 . Pregnant woman 5 . Inability comply study and/or followup procedure . 6 . Patients &lt; 18 year age .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Pancreatic Cancer</keyword>
	<keyword>Adenocarcinoma Pancreas</keyword>
	<keyword>Intratumoral gemcitabine level</keyword>
	<keyword>Pancreatic surgery</keyword>
	<keyword>Pharmacokinetic testing</keyword>
	<keyword>PK</keyword>
	<keyword>Gemcitabine</keyword>
	<keyword>Gemcitabine Hydrochloride</keyword>
	<keyword>Gemzar</keyword>
</DOC>